RS60211B1 - Kombinovana terapija - Google Patents
Kombinovana terapijaInfo
- Publication number
- RS60211B1 RS60211B1 RS20200297A RSP20200297A RS60211B1 RS 60211 B1 RS60211 B1 RS 60211B1 RS 20200297 A RS20200297 A RS 20200297A RS P20200297 A RSP20200297 A RS P20200297A RS 60211 B1 RS60211 B1 RS 60211B1
- Authority
- RS
- Serbia
- Prior art keywords
- gemcitabine
- phosphate
- alaninyl
- cancer
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/054158 WO2017109444A1 (en) | 2015-12-23 | 2015-12-23 | Combination therapy |
| GBGB1609770.1A GB201609770D0 (en) | 2016-06-03 | 2016-06-03 | Combination therapy |
| EP16820005.3A EP3393478B1 (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
| PCT/GB2016/054018 WO2017109486A1 (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60211B1 true RS60211B1 (sr) | 2020-06-30 |
Family
ID=57681677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20200297A RS60211B1 (sr) | 2015-12-23 | 2016-12-21 | Kombinovana terapija |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20190022117A1 (enExample) |
| EP (2) | EP3738595A1 (enExample) |
| JP (1) | JP6898329B2 (enExample) |
| KR (1) | KR20180096698A (enExample) |
| CN (1) | CN108697725A (enExample) |
| AU (1) | AU2016375861B2 (enExample) |
| CA (1) | CA3008749C (enExample) |
| CY (1) | CY1122835T1 (enExample) |
| DK (1) | DK3393478T3 (enExample) |
| EA (1) | EA037459B1 (enExample) |
| ES (1) | ES2778933T3 (enExample) |
| HR (1) | HRP20200423T1 (enExample) |
| HU (1) | HUE050290T2 (enExample) |
| IL (1) | IL260076A (enExample) |
| LT (1) | LT3393478T (enExample) |
| MA (1) | MA51576A (enExample) |
| MD (1) | MD3393478T2 (enExample) |
| ME (1) | ME03677B (enExample) |
| MX (1) | MX383988B (enExample) |
| MY (1) | MY194629A (enExample) |
| PH (1) | PH12018501339A1 (enExample) |
| PL (1) | PL3393478T3 (enExample) |
| PT (1) | PT3393478T (enExample) |
| RS (1) | RS60211B1 (enExample) |
| SG (1) | SG11201805184TA (enExample) |
| SI (1) | SI3393478T1 (enExample) |
| SM (1) | SMT202000154T1 (enExample) |
| WO (1) | WO2017109486A1 (enExample) |
| ZA (1) | ZA201804155B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3235824B1 (en) | 2012-11-16 | 2019-03-27 | University College Cardiff Consultants Limited | Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate |
| HRP20180007T1 (hr) | 2014-06-25 | 2018-02-23 | NuCana plc | Formulacija koja sadrži gemcitabin-predlijek |
| PL3160978T3 (pl) | 2014-06-25 | 2020-11-30 | NuCana plc | Proleki gemcytabiny |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| CN108135920A (zh) | 2015-10-05 | 2018-06-08 | 努卡那有限公司 | 组合疗法 |
| MX386478B (es) | 2015-12-11 | 2025-03-18 | Laurus Labs Ltd | Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031. |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| KR20150044838A (ko) * | 2012-08-13 | 2015-04-27 | 레귤론, 인코퍼레이티드. | 리포플라틴을 이용한 암 치료방법 |
| WO2014078295A1 (en) * | 2012-11-13 | 2014-05-22 | BoYen Therapeutics, Inc. | Gemcitabine prodrugs and uses thereof |
| LT3197456T (lt) * | 2015-05-14 | 2018-07-10 | NuCana plc | Vėžio gydymas |
| CN108135920A (zh) * | 2015-10-05 | 2018-06-08 | 努卡那有限公司 | 组合疗法 |
-
2016
- 2016-12-21 EP EP20160070.7A patent/EP3738595A1/en not_active Withdrawn
- 2016-12-21 US US16/065,498 patent/US20190022117A1/en not_active Abandoned
- 2016-12-21 MD MDE20181039T patent/MD3393478T2/ro not_active IP Right Cessation
- 2016-12-21 EA EA201891473A patent/EA037459B1/ru unknown
- 2016-12-21 WO PCT/GB2016/054018 patent/WO2017109486A1/en not_active Ceased
- 2016-12-21 ES ES16820005T patent/ES2778933T3/es active Active
- 2016-12-21 CN CN201680082464.9A patent/CN108697725A/zh active Pending
- 2016-12-21 HR HRP20200423TT patent/HRP20200423T1/hr unknown
- 2016-12-21 MY MYPI2018001015A patent/MY194629A/en unknown
- 2016-12-21 MA MA051576A patent/MA51576A/fr unknown
- 2016-12-21 JP JP2018532746A patent/JP6898329B2/ja active Active
- 2016-12-21 AU AU2016375861A patent/AU2016375861B2/en not_active Ceased
- 2016-12-21 KR KR1020187020533A patent/KR20180096698A/ko not_active Ceased
- 2016-12-21 LT LTEP16820005.3T patent/LT3393478T/lt unknown
- 2016-12-21 DK DK16820005.3T patent/DK3393478T3/da active
- 2016-12-21 EP EP16820005.3A patent/EP3393478B1/en active Active
- 2016-12-21 RS RS20200297A patent/RS60211B1/sr unknown
- 2016-12-21 PT PT168200053T patent/PT3393478T/pt unknown
- 2016-12-21 ME MEP-2020-56A patent/ME03677B/me unknown
- 2016-12-21 MX MX2018007772A patent/MX383988B/es unknown
- 2016-12-21 PL PL16820005T patent/PL3393478T3/pl unknown
- 2016-12-21 SI SI201630680T patent/SI3393478T1/sl unknown
- 2016-12-21 CA CA3008749A patent/CA3008749C/en active Active
- 2016-12-21 HU HUE16820005A patent/HUE050290T2/hu unknown
- 2016-12-21 SM SM20200154T patent/SMT202000154T1/it unknown
- 2016-12-21 SG SG11201805184TA patent/SG11201805184TA/en unknown
-
2018
- 2018-06-17 IL IL260076A patent/IL260076A/en unknown
- 2018-06-21 ZA ZA2018/04155A patent/ZA201804155B/en unknown
- 2018-06-21 PH PH12018501339A patent/PH12018501339A1/en unknown
-
2020
- 2020-03-17 CY CY20201100245T patent/CY1122835T1/el unknown
-
2022
- 2022-06-21 US US17/845,878 patent/US20230149436A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220323475A1 (en) | Combination therapy for cancer | |
| US20230149436A1 (en) | Combination therapy | |
| AU2015418015B2 (en) | Combination therapy | |
| DK3119794T3 (en) | FORMULA CONTAINING A GEMCITABIN PRODRUG | |
| RS60968B1 (sr) | Prolekovi gemcitabina | |
| HK40038228A (en) | Combination therapy | |
| WO2019043386A1 (en) | COMBINATION THERAPY | |
| HK1255110B (en) | Combination therapy | |
| NZ743529A (en) | Combination therapy | |
| BR112018012956B1 (pt) | Uso de gencitabina-[fenil-(benzóxi-l-alaninil)]-fosfato ou um sal ou solvato farmaceuticamente aceitável do mesmo no tratamento de câncer | |
| BR112018006880B1 (pt) | Uso de gencitabina-[fenil-benzóxi-l-alaninil)]-fosfato ou um sal farmaceuticamente aceitável ou solvato da mesma e carboplatina no tratamento de câncer |